RWM
CPRX

Rialto Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Rialto Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$520 Buy
+21
New +$500 ﹤0.01% 1350

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Rialto Wealth Management's CPRX Position: Q1 2026 in Review

Rialto Wealth Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 21 shares worth $520. The stake represents ﹤0.01% of the portfolio and ranks #1350 among its holdings.

380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Rialto Wealth Management held 21 shares of Catalyst Pharmaceutical worth $520 as of Q1 2026.
  • Catalyst Pharmaceutical was a new Rialto Wealth Management position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1350 holding.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.